Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of UI009 vs UIC202005 in Healthy Volunteers
NCT07110740Phase 1Completed
- Sponsor
- Korea United Pharm Inc.
- Start
- Oct 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of UI009 in asthma and chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Korea United Pharm Inc. Primary endpoints: Maximum Plasma Concentration of Fluticasone propionate at Day 8, Area Under the Concentration-Time Curve to the Last Measurable Concentration of Fluticasone propionate at Day 8 and 3 more. Started Oct 2024; status: completed.
02
Drugs
UI009
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT07110740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07110740.